BACKGROUND: Mutations in the leucine-rich repeat kinase 2 gene are the most frequent cause of familial and sporadic Parkinson's disease, and G2019S is the most common leucine-rich repeat kinase 2 mutation across several Mediterranean countries. METHODS: One hundred ninety-two patients with Parkinson's disease from Campania, a region in southern Italy, were screened for R1441C/H/G and G2019S by direct sequencing and SfcI digestion. RESULTS: Among 192 patients with Parkinson's disease (mean age±SD, 63.9±11.8 years; disease onset, 54.0±12.5 years; family history for Parkinson's disease or tremor, 45%), 8 carried a heterozygous R1441C mutation, whereas only 1 had the G2019S mutation. All R1441C patients originate from the province of Naples and share the same haplotype, suggesting a founder effect. CONCLUSIONS: G2019S is not ubiquitously the most common leucine-rich repeat kinase 2 mutation; in Campania R1441C is more frequent. Region-specific mutation prevalence data should be taken into account for a sensitive and cost-effective molecular diagnosis and counseling of patients with Parkinson's disease.
BACKGROUND: Mutations in the leucine-rich repeat kinase 2 gene are the most frequent cause of familial and sporadic Parkinson's disease, and G2019S is the most common leucine-rich repeat kinase 2 mutation across several Mediterranean countries. METHODS: One hundred ninety-two patients with Parkinson's disease from Campania, a region in southern Italy, were screened for R1441C/H/G and G2019S by direct sequencing and SfcI digestion. RESULTS: Among 192 patients with Parkinson's disease (mean age±SD, 63.9±11.8 years; disease onset, 54.0±12.5 years; family history for Parkinson's disease or tremor, 45%), 8 carried a heterozygous R1441C mutation, whereas only 1 had the G2019S mutation. All R1441C patients originate from the province of Naples and share the same haplotype, suggesting a founder effect. CONCLUSIONS:G2019S is not ubiquitously the most common leucine-rich repeat kinase 2 mutation; in Campania R1441C is more frequent. Region-specific mutation prevalence data should be taken into account for a sensitive and cost-effective molecular diagnosis and counseling of patients with Parkinson's disease.
Authors: Anna De Rosa; Teresa Pellegrino; Sabina Pappatà; Maria Teresa Pellecchia; Silvio Peluso; Francesco Saccà; Paolo Barone; Alberto Cuocolo; Giuseppe De Michele Journal: J Nucl Cardiol Date: 2015-12-01 Impact factor: 5.952
Authors: Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray Journal: Biochemistry Date: 2013-03-01 Impact factor: 3.162
Authors: Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-04-25 Impact factor: 3.568
Authors: Chen Yao; William M Johnson; Yue Gao; Wen Wang; Jinwei Zhang; Maria Deak; Dario R Alessi; Xiongwei Zhu; John J Mieyal; Hanno Roder; Amy L Wilson-Delfosse; Shu G Chen Journal: Hum Mol Genet Date: 2012-10-12 Impact factor: 6.150
Authors: Max Sloan; Javier Alegre-Abarrategui; Dawid Potgieter; Anna-Kristin Kaufmann; Richard Exley; Thierry Deltheil; Sarah Threlfell; Natalie Connor-Robson; Katherine Brimblecombe; Rebecca Wallings; Milena Cioroch; David M Bannerman; J Paul Bolam; Peter J Magill; Stephanie J Cragg; Paul D Dodson; Richard Wade-Martins Journal: Hum Mol Genet Date: 2016-01-06 Impact factor: 6.150